

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/030489 A1

(43) International Publication Date
10 February 2022 (10.02.2022)

(51) International Patent Classification:

A61K 31/5513 (2006.01) A61P 27/02 (2006.01)
A61K 9/06 (2006.01) A61P 27/06 (2006.01)
A61K 9/08 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/JP2021/028770

(22) International Filing Date:

03 August 2021 (03.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020-132626 04 August 2020 (04.08.2020) JP

(71) Applicants: **SANTEN PHARMACEUTICAL CO., LTD.** [JP/JP]; 4-20, Ofuka-cho, Kita-ku, Osaka-shi, Osaka, 5308552 (JP). **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors: **INABA, Takaaki**; c/o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP). **KATO, Masatomo**; c/o SANTEN PHARMACEUTICAL CO., LTD., 8916-16, Takayama-cho, Ikoma-shi, Nara, 6300101 (JP).

(74) Agent: **YAMAO, Norihito** et al.; AOYAMA & PARTNERS, Umeda Hankyu Bldg. Office Tower, 8-1, Kaku-da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR SUPPRESSING MYOPIA PROGRESSION

(57) Abstract: The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidiny]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidiny]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.

WO 2022/030489 A1